Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

58.44
-1.5600-2.60%
Post-market: 58.28-0.1647-0.28%19:46 EDT
Volume:2.08M
Turnover:122.59M
Market Cap:11.29B
PE:154.20
High:60.16
Open:59.81
Low:58.39
Close:60.00
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.11
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.79
PE(LYR):32.47

Loading ...

BioMarin Q1 GAAP net income drops 43% to $106 million; revenue rises 3% to $766 million

Reuters
·
May 05

Biomarin Pharmaceutical Q1 Adj. EPS $0.76 Misses $0.79 Estimate, Sales $766.208M Beat $755.610M Estimate

Benzinga Earnings
·
May 05

Biomarin Pharmaceutical Outlook FY Adjusted EPS USD 4.85-5.05

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 EPS USD 0.54

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 Adjusted EPS USD 0.76 VS. Ibes Estimate USD 0.75

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 Net Income USD 106 Million

THOMSON REUTERS
·
May 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

How Investors Are Reacting To BioMarin (BMRN) VOXZOGO Data Showing Benefits Beyond Height in Achondroplasia

Simply Wall St.
·
May 04

BioMarin announces new research from studies of Voxzogo

TIPRANKS
·
May 04

BioMarin says VOXZOGO long-term trials improve arm span, maintain bone density in achondroplasia

Reuters
·
May 03

Biomarin Presents New Data on the Effect of Long-Term Treatment With Voxzogo® (Vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

THOMSON REUTERS
·
May 03

BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a share - Earnings Preview

Reuters
·
May 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

MT Newswires Live
·
Apr 27

BioMarin completes acquisition of Amicus Therapeutics

TIPRANKS
·
Apr 27

BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion

Reuters
·
Apr 27

Biomarin Completes Acquisition of Amicus Therapeutics

THOMSON REUTERS
·
Apr 27

BioMarin to host first-quarter results conference call and webcast

Reuters
·
Apr 27

Morgan Stanley Resumes BioMarin Pharmaceutical at Overweight With $120 Price Target

MT Newswires Live
·
Apr 27

BioMarin resumed with an Overweight at Morgan Stanley

TIPRANKS
·
Apr 27